CFI-401870 is a orally bioavailable, potent tyrosine threonine kinase (TTK) Inhibitor (TTK IC50 < 10 nM, HCT116 GI50 < 0.1 μM). CFI-401870 displayed low off-target activity (>500×), and microsomal stability (T(1/2) > 30 min). CFI-401870 recapitulated the phenotype of TTK RNAi, demonstrated in vivo tumor growth inhibition upon orally bioavailable dosing, and was selected for preclinical evaluation. References: Liu Y, Lang Y, Patel NK, Ng G, Laufer R, Li SW, Edwards L, Forrest B, Sampson PB, Feher M, Ban F, Awrey DE, Beletskaya I, Mao G, Hodgson R, Plotnikova O, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents. J Med Chem. 2015 Apr 23;58(8):3366-92. doi: 10.1021/jm501740a. Epub 2015 Apr 3. PubMed PMID: 25763473.

纯度：≥98%

CAS：1430741-35-7